Eupraxia Pharmaceuticals Inc.
$7.2
▼
-2.18%
2026-04-21 06:40:01
www.eupraxiapharma.com
NCM: EPRX
Explore Eupraxia Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$599.04 M
Current Price
$7.2
52W High / Low
$12.86 / $4.38
Stock P/E
—
Book Value
$1.01
Dividend Yield
—
ROCE
-47.73%
ROE
-68.76%
Face Value
—
EPS
$-1.03
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
49
Beta
1.42
Debt / Equity
0.19
Current Ratio
15.12
Quick Ratio
15.12
Forward P/E
-10.68
Price / Sales
—
Enterprise Value
$369.65 M
EV / EBITDA
-9.66
EV / Revenue
—
Rating
Strong Buy
Target Price
$14.39
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
| 2. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
| 3. | Rezolute, Inc. | $3.37 | — | $322.5 M | — | -48.84% | -74.02% | $11.46 / $1.07 | $1.23 |
| 4. | Upstream Bio, Inc. | $9.99 | — | $543.66 M | — | -47.12% | -35.44% | $33.68 / $7.25 | $6.26 |
| 5. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
| 6. | Crescent Biopharma, Inc. | $21.69 | — | $575.8 M | — | -74.74% | -1.61% | $29 / $8.72 | $5.99 |
| 7. | Achieve Life Sciences, Inc. | $4.25 | — | $226.27 M | — | -167.79% | -2.58% | $6.03 / $1.95 | $0.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -16.16 M | -6.88 M | -8.26 M | -7.12 M | -7.48 M | — |
| Net Profit | -16.71 M | -6.36 M | -8.74 M | -6.76 M | -7.51 M | — |
| EPS in Rs | -0.27 | -0.1 | -0.14 | -0.11 | -0.12 | -0.17 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -38.43 M | -27 M | -27.85 M | -17.62 M |
| Net Profit | -38.58 M | -25.5 M | -28.22 M | -18.49 M |
| EPS in Rs | -0.63 | -0.41 | -0.46 | -0.3 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 86.15 M | 34.94 M | 20.27 M | 19.12 M |
| Total Liabilities | 5.7 M | 3.1 M | 19.37 M | 11.91 M |
| Equity | 82.04 M | 33.4 M | 2.22 M | 7.79 M |
| Current Assets | 85.1 M | 34.44 M | 19.8 M | 18.59 M |
| Current Liabilities | 5.63 M | 3.1 M | 19.37 M | 3.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -28.55 M | -29.99 M | -20.75 M | -14.4 M |
| Investing CF | -0.59 M | -0.08 M | -0.07 M | 9.83 M |
| Financing CF | 76.06 M | 45.78 M | 21.08 M | 10.8 M |
| Free CF | -29.14 M | -30.1 M | -20.82 M | -14.63 M |
| Capex | -0.59 M | -0.1 M | -0.07 M | -0.24 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 9.63% | -52.63% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.